

Page 13, line 17, before ":", please insert --(SEQ ID NO:5)--.

Page 13, line 19, before "etc.", please insert --(SEQ ID NO:6)--.

Page 16, line 22, before "at the", please insert --(SEQ ID NO:7)--.

Page 16, line 24, before "at the", please insert --(SEQ ID NO:8)--.

Page 16, line 26, before "at the", please insert --(SEQ ID NO:9)--.

Page 19, line 17, please delete "Gene Pulser" and substitute therefor

--GENE PULSER (trademark)--.

Page 21, line 9, please delete "Immobilon" and substitute therefor

--IMMOBILON (trademark)--.

Page 22, line 23, after "ELISA", please insert --(Enzyme Linked ImmunoSorbent Assay)--.

Page 24, line 22, please delete "Nembutal" and substitute therefor

--NEMBTAL (trademark) (manufactured by Abbot)--.

IN THE CLAIMS:

Please cancel claims 1 and 12-13.

Please amend claims 2, 5 and 9-11 as follows.

Claims 2 and 5, line 1, please delete "1" and substitute therefor --14--.

Claim 9, line 2, please delete "1" and substitute therefor --2--, and after "8", insert
--and 14--.

Claim 10, line 2, please delete "1" and substitute therefor --2--, and line 3, after "8",
insert --and 14--.

Claim 11, line 3, please delete "1" and substitute therefor --2--, and after "8", insert
--and 14--.

Please add new claims 14-17 as follows.

--14. A fusion protein comprising a polypeptide causing an antibody-antigen reaction with Mycoplasma gallisepticum immune serum or Mycoplasma gallisepticum infected serum and a polypeptide derived from Herpesvirus outer membrane protein, said polypeptide derived from the outer membrane protein being ligated with the polypeptide causing an antibody-antigen reaction with Mycoplasma gallisepticum immune serum or Mycoplasma gallisepticum infected serum at the N terminus thereof.

15. A fusion protein according to claim 14, wherein the polypeptide derived from herpesvirus outer membrane protein contains at least a signal sequence of the herpesvirus outer membrane protein.

16. A recombinant live vaccine for anti-fowl Mycoplasma gallisepticum infection comprising as an effective ingredient a recombinant Avipox virus in which a DNA coding for the fusion protein according to any one of claims 2 through 8 and 14 has been inserted, wherein the fusion protein is capable, upon administration into a host cell, of immunizing that cell against subsequent infection with Mycoplasma gallisepticum.

17. A trivalent live vaccine for anti-fowl Mycoplasma gallisepticum infection and anti-Marek's disease infection comprising as an effective ingredient a DNA coding for the fusion protein according to any one of claims 3 and 4, wherein the fusion protein is capable, upon administration into a host cell, of immunizing that cell against subsequent infection with Mycoplasma gallisepticum.--